US Pat. No. 9,610,331

METHODS FOR HEMATOPOIETIC PRECURSOR MOBILIZATION

Yeda Research and Develop...

1. A method of increasing mobilization of hematopoietic precursors from the bone marrow to the peripheral blood in a human
subject, wherein the subject has a hematologic disorder or condition that is not Hodgkin's lymphoma, the method comprising:
(a) administering to the subject Clexane or Dabigatran;
(b) administering to the subject a mobilization factor comprising G-CSF;
(c) determining the efficacy of said mobilization; and subsequently
(d) harvesting said hematopoietic precursors from the peripheral blood, thereby increasing said mobilization of said hematopoietic
precursors from said bone marrow to said peripheral blood in said human subject.

US Pat. No. 9,122,955

METHOD AND SYSTEM OF CLASSIFYING MEDICAL IMAGES

Ramot at Tel-Aviv Univers...

1. A method of generating a category model for classifying medical images, comprising:
providing a plurality of anatomical medical images imaging at least one internal organ or area of a body;
in each of said plurality of anatomical medical images identifying a plurality of image patches, each image patch is represented
by a plurality of repeatable multidimensional features in a pixel area of a respective anatomical medical image and image
coordinates of said pixel area in said respective anatomical medical image, wherein said plurality of repeatable multidimensional
features of each of the plurality of image patches comprises at least one noise reduction based coefficient and a gray level
feature of the image patch;

for each of said image patches, weighting at least some of the noise reduction based coefficient, the gray level feature,
and the image coordinates, wherein said weighting is tuned experimentally on a cross-validation set;

generating a plurality of visual words by clustering said plurality of image patches represented by said weighted at least
one noise reduction based coefficient, gray level feature, and image coordinates of each one of said plurality of image patches;

modeling a category model mapping a relation between said plurality of visual words;
outputting said category model adapted to categorize a pathology in a new anatomical medical image based on a new set of image
patches from said new anatomical medical image and the coordinates of pixel areas of said new set of image patches in said
new anatomical medical image,

wherein at least one of said providing, generating, modeling, and outputting is performed by at least one processor.

US Pat. No. 9,492,480

IRON OXIDE NANOPARTICLES FOR USE IN TREATING NON-INFECTIOUS INFLAMMATORY DISORDERS

RAMOT AT TEL AVIV UNIVERS...

1. A method for treating myocardial infarction in a human subject suffering from myocardial infarction, the method comprising:
administering to the subject in need an amount of an active agent effective to treat myocardial infarction, said active agent
being iron oxide nanoparticles,

wherein said method does not include a step of magnetic resonance imaging of myocardial infarction using iron oxide particles.
US Pat. No. 9,090,943

METHODS FOR DETECTING AN INCREASED SUSCEPTIBILITY TO CANCER

Rosetta Genomics Ltd., R...

1. A method for detecting a risk of developing breast or ovarian cancer in a human subject carrying a BRCA2 mutation comprising
detecting a nucleic acid sequence of a polymorphism of a microRNA-related gene or variant thereof comprising SEQ ID NO: 1
by nucleic acid amplification or extension using any one of SEQ ID NO: 26, SEQ ID NO: 42 or SEQ ID NO: 58 as a primer, comparing
the polymorphic pattern of the microRNA-related gene or variant thereof to a reference wild-type allele in a human subject
not carrying the BRCA2 mutation, wherein the presence of a C/T heterozygote genotype at the rs11169571 SNP in said microRNA-related
gene or variant thereof relative to the reference wild-type allele is indicative of an increased risk of developing breast
or ovarian cancer in said human subject, and determining whether the human subject has an increased risk of developing breast
or ovarian cancer based on the presence of the C/T heterozygote genotype at the rs11169571 SNP in the microRNA-related gene
or variant thereof relative to the reference wild-type allele.
US Pat. No. 9,068,232

GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF KIDNEY TUMORS

Rosetta Genomics Ltd., R...

1. A method for distinguishing between oncocytoma, clear cell renal cell carcinoma (RCC), papillary (chromaphil) RCC and chromophobe
RCC in a human subject with renal cancer, the method comprising:
(a) obtaining a kidney tumor sample from the human subject;
(b) determining an expression profile in said sample of SEQ ID NOS: 1-24 by contacting the sample with probes that hybridize
to each of SEQ ID NOS: 1-24, wherein each probe comprises the complement of one of SEQ ID NOs: 1-24, and wherein the probes
are attached to a solid substrate;

(c) comparing said expression profile to a reference threshold value by using a classifier algorithm; and
(d) determining whether the human subject has oncocytoma, clear cell renal cell carcinoma (RCC), papillary (chromaphil) RCC
or chromophobe RCC based on altered expression of SEQ ID NOS: 1-24 in the sample relative to the reference threshold value;
wherein increased expression of SEQ ID NOS: 3, 5, 7, 9, 11, 12, 16, 18, 19 and 23 relative to the reference threshold is indicative
of the presence of oncocytoma; wherein increased expression of SEQ ID NOS: 1, 2, 4, 6, 8, 10, 13-15, 17, 20-22 and 24 is indicative
of the presence of chromophobe RCC; wherein increased expression of SEQ ID NOS: 3, 5-7, 9, 12 and 24 is indicative of the
presence of clear cell RCC; and wherein increased expression of SEQ ID NOS: 1, 2, 4, 8, 10, 11 and 13-23 is indicative of
the presence of papillary RCC.

US Pat. No. 9,180,152

METHOD FOR TREATING PSORIASIS

NIKKEN SOHONSHA CORPORATI...

1. A method for treating plaque psoriasis in a subject in need thereof comprising orally administering to the subject a pharmaceutically
effective amount of crude Dunaliella powder, wherein the Dunaliella powder comprises 9-cis ?-carotene to all-trans isomers of ?-carotene (BC) having a weight ratio of at least 1:1, respectively.
US Pat. No. 9,238,838

MICRORNA PATTERNS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF MELANOMA

Ramot at Tel Aviv Univers...

1. A method for diagnosing melanoma in a subject, the method comprising:
(a) obtaining from the subject a sample of peripheral blood comprising RNA; and
(b) determining, in said RNA, the presence of a plurality of oncogenic miRNAs (miRs), comprising miR-374a and at least one
miRNA selected from the group consisting of: miR-301a, SNORD-38b, miR-29c, miR-342-3p, miR-451 and miR-29a,

wherein the presence of the plurality of oncogenic miRs is indicative of the subject having melanoma.

US Pat. No. 9,092,878

METHOD AND SYSTEM FOR PROCESSING AN IMAGE

Ramot at Tel-Aviv Univers...

1. A method of processing an image having a plurality of picture-elements, comprising:
preprocessing the image to selectively enhance contrast of some picture-elements of the image using a mapping function for
diminishing image data with intensity levels below an intensity threshold, thereby providing a preprocessed image, said mapping
function having a plateau region for intensity levels below said intensity threshold, and increasing monotonically for any
intensity level of said image above said intensity threshold;

employing a companding procedure for said preprocessed image, thereby providing a processed image; and
outputting said processed image to a computer readable medium or a display device.
US Pat. No. 9,808,488

ISOLATED POPULATIONS OF RENAL STEM CELLS AND METHODS OF ISOLATING AND USING SAME

Tel HaShomer Medical Rese...

1. A method of treating a renal damage in a subject in need thereof comprising administering to the subject a therapeutically
effective amount of renal cells comprising at least 50% cells having a NCAM+ signature, thereby treating the renal damage
in the subject.
US Pat. No. 9,261,507

ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME

Tel Hashomer Medical Rese...

1. A method for identifying a biological sample having cancer cells characterized by over-expression of CEACAM1 as compared
to non-cancer cells, comprising:
a) obtaining a control level of immune-complex formation between CEACAM1 and an anti-CEACAM1 antibody or antibody fragment
that recognizes CEACAM1, and that comprises the same CDR sequences in the same orientation as the CDRs of the antibody produced
from a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 in a biological sample from a healthy
subject;

b) obtaining a biological sample from a subject suspected of having cancer cells characterized by over-expression of CEACAM1
as compared to non-cancer cells;

c) contacting said biological sample of step b) with said anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1
and determining the level of immune-complex after said contacting; and

d) identifying that said biological sample from said subject suspected of having cancer cells has cancer cells characterized
by over-expression of CEACAM1 as compared to non-cancer cells if there is a statistically significant higher level of immune-complexes
of said biological sample from said subject suspected of having cancer cells characterized by over-expression of CEACAM1 as
compared to non-cancer cells than the control level.

US Pat. No. 9,103,836

PROCOLLAGEN C-PROTEINASE ENHANCER (PCPE) BIOMARKER FOR BONE FORMATION

TEL HASHOMER MEDICAL RESE...

1. A method of analyzing bone formation or determination of cell state with regard to differentiation of osteoblasts and/or
fibroblasts in a subject, the method comprising:
detecting PCPE isoforms in a biological sample from said subject; and
comparing the glycosylation pattern of said PCPE isoforms from said sample of biological fluid with a glycosylation pattern
of PCPE isoforms of a predetermined standard or a sample obtained from healthy individuals, wherein a difference in the glycosylation
pattern of PCPE isoforms in the biological sample from the subject relative to the glycosylation pattern of PCPE isoforms
in the sample of the predetermined standard or healthy individuals is indicative of a difference in bone formation or cell
state relative to the standard or healthy individuals.

US Pat. No. 9,481,894

METHODS OF INDUCING REGULATED PANCREATIC HORMONE PRODUCTION IN NON-PANCREATIC ISLET TISSUES

TEL HASHOMER MEDICAL RESE...

1. An in vitro method of increasing PDX-1 induction of a pancreatic islet cell phenotype or function in a population of human
non-pancreatic primary cells, said method comprising the steps of:
(1) contacting a population of human non-pancreatic primary cells with a composition comprising a nucleic acid encoding a
PDX-1 polypeptide, wherein said PDX-1 is ectopically expressed within said cell population,

(2) concurrently contacting said cell population with a composition comprising an effective amount of nicotinamide and epidermal
growth factor; and

(3) measuring the expression levels of PDX-1 in the contacted cells of step (2),
wherein said concurrent contacting of said population with a composition comprising an effective amount of nicotinamide and
epidermal growth factor increases PDX-1 induction of a pancreatic islet cell phenotype or function.

US Pat. No. 9,340,823

GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF KIDNEY TUMORS

Rosetta Genomics, Ltd., ...

1. A method for classifying a kidney tumor sample obtained from a human subject as oncocytoma, clear cell renal cell carcinoma
(RCC), papillary RCC, or chromophobe RCC, the method comprising:
(a) obtaining a kidney tumor sample from the human subject;
(b) determining by real-time PCR (RT-PCR) an expression profile of SEQ ID NOS: 1, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24-26,
28, 30, 32, 34, 36, 38, 41, 45, 47, 48, 56, 58, 60, 62, and 66 in the sample, wherein said RT-PCR comprises contacting the
sample with forward and reverse primers, wherein each forward primer comprises at least 15-21 nucleotides identical to one
of SEQ ID NOS: 1, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24-26, 28, 30, 32, 34, 36, 38, 41, 45, 47, 48, 56, 58, 60, 62, and
66, and wherein the forward primer comprising at least 15-21 nucleotides identical to SEQ ID NO: 14 comprises the sequence
of SEQ ID NO: 84;

(c) comparing said expression profile to one or more reference values; and
(d) classifying the kidney tumor sample as oncocytoma, clear cell RCC, papillary RCC, or chromophobe RCC based on the expression
profile of SEQ ID NOS: 1, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24-26, 28, 30, 32, 34, 36, 38, 41, 45, 47, 48, 56, 58, 60,
62, and 66 in the sample relative to the reference value, wherein:

an increase in the expression of SEQ ID NOS: 12, 14, 18, 25, 26, 28, 30, 36, 38, 41, 48, and 66 in the sample relative to
the reference value is indicative of the presence of oncocytoma;

an increase in the expression of SEQ ID NOS: 32, 34, 36, 56, 58, 60, and 62 in the sample relative to the reference value
is indicative of the presence of chromophobe RCC;

an increase in the expression of SEQ ID NOS: 1, 6, 16, 20, 22, 24, and 41 in the sample relative to the reference value is
indicative of the presence of clear cell RCC; and

an increase in the expression of SEQ ID NOS: 4, 8, 10, 45, and 47 in the sample relative to the reference value is indicative
of the presence of papillary RCC.

US Pat. No. 9,982,236

CELL POPULATIONS, METHODS OF TRANSDIFFERENTIATION AND METHODS OF USE THEREOF

ORGENESIS LTD., Tel Aviv...

1. A method of producing a transdifferentiated population of cells having a mature pancreatic beta cell phenotype and function comprising:a. obtaining an adult mammalian liver cell population enriched for cells predisposed to transdifferentiation, wherein the enriched population is obtained by providing a population of adult mammalian liver cells and isolating a sub-population of cells comprising:
(i) an active wingless-type MMTV integration site family (Wnt) signaling pathway; or
(ii) increased expression from a glutamine synthase response element (GSRE); or
(iii) an increased expression of homer scaffolding protein 1 (HOMER1), lysosomal associated membrane protein 3 (LAMP3), or bone morphogenetic protein receptor type 2 (BMPR2), or any combination thereof; or
(iv) a decreased expression of ATP binding cassette subfamily B member 1 (ABCB1), integrin subunit alpha 4 (ITGA4), ATP binding cassette subfamily B member 4 (ABCB4), or prion protein (PRNP), or any combination thereof; or any combination thereof;
b. contacting said enriched adult mammalian liver cell population with a pancreatic and duodenal homeobox (PDX-1) polypeptide or a nucleic acid encoding a PDX-1 polypeptide under conditions to allow uptake of the said polypeptides or nucleic acids at a first time period;
c. contacting the population of cells of step (b) with a paired box gene 4 (Pax-4) polypeptide, or a neurogenic differentiation 1 (NeuroD1) polypeptide, or a nucleic acid encoding a Pax-4 polypeptide, or a nucleic acid encoding a NeuroD1 polypeptide under conditions to allow uptake of the said polypeptides or nucleic acids at a second time period; and
d. contacting the population of cells of step (c) with a MAF bZIP transcription factor A (MafA) polypeptide or a nucleic acid encoding a MafA polypeptide under conditions to allow uptake of the polypeptide or the nucleic acid at a third time period;thereby producing a transdifferentiated population of cells having a mature pancreatic beta cell phenotype and function.

US Pat. No. 9,711,253

METHOD AND SYSTEM FOR ELECTRON RADIOTHERAPY

Tel HaShomer Medical Rese...

1. A radiotherapy system, comprising:
an electron beam generator, for generating an electron beam, at an energy of at least 60 MeV, directed to a surface of a living
body to propagate in said living body;

at least two coils, for generating a multipole magnetic field within said living body; and
a controller having a circuit configured for controlling said at least two coils to generate and to dynamically redirect the
multipole magnetic field, by applying an alternating current to the at least two coils; the multipole magnetic field concentrates
said electron beam while electrons of said beam propagate in said living body, and wherein the controller having the circuit
is configured for controlling said electron beam generator to dynamically shift said electron beam;

wherein said shifting of the electron beam with the electron beam generator and said redirecting of the magnetic field with
the at least two coils occurs synchronously and results in the delivery of an energy-dose into said living body with an energy-dose
peak at an internal target location which is at a depth of at least 7 cm in said living body;

wherein said controller is configured to control said electron beam and said at least two coils such that said energy-dose
has a symmetric profile with respect to each of an x, y and z axis.

US Pat. No. 9,655,509

SYSTEM AND METHOD FOR OBJECTIVE CHROMATIC PERIMETRY ANALYSIS USING PUPILLOMETER

Tel Hashomer Medical Rese...

1. A method for determining the state of health of an eye using a pupillometer to provide an objective chromatic perimetry
analysis test, wherein:
the pupillometer comprises a processor, at least one camera, and a testing compartment provided in the form of a substantially
hemispheric bowl;

the substantially hemispheric bowl comprises a plurality of chromatic beam emitters arranged about a visual field forming
a plurality of visual field testing points;

the chromatic beam emitters generate a plurality of chromatic stimuli about the visual field testing points;
the chromatic stimuli comprise a first chromatic beam stimulus and a second chromatic beam stimulus;
at least one of the first chromatic beam stimulus and the second chromatic beam stimulus employs a wavelength that stimulates
ganglion cells;

the testing compartment further comprises a light adaptation emitter;
the inner surface further comprises a fixation point opposite a subject's line of sight;
the at least one camera records pupil contraction in response to the first and second chromatic beam stimuli;
the processor controls the chromatic beam emitters and the stimulus parameters of the chromatic beam emitters;
the processor processes data associated with and generated by the first and second chromatic beam stimuli and the camera;
and

the method comprises
generating quantitative pupillary light reflex (PLR) measurements of a pupillary light reflex (PLR) in response to chromatic
beam stimuli presented at the plurality of visual field testing points,

determining ratios of the quantitative PLR measurements at the plurality of visual field testing points, wherein each of the
ratios at each testing point represents a quantitative PLR measurement at the first chromatic beam stimulus relative to a
quantitative PLR measurement at the second chromatic beam stimulus, and

determining the state of health of the eye utilizing the ratios,wherein (i) the first chromatic beam stimulus employs a shorter-wavelength chromatic beam, relative to the second chromatic
beam stimulus, (ii) the second chromatic beam stimulus employs a longer-wavelength chromatic beam, relative to the first chromatic
beam stimulus, and (iii) the wavelengths of the first chromatic beam stimulus and the second chromatic beam stimulus are selected
from the visual spectrum spanning from about 390 nm to about 750 nm.

US Pat. No. 9,943,286

ULTRASONOGRAPHIC IMAGES PROCESSING

Tel HaShomer Medical Rese...

1. A computerized method of adapting a presentation of ultrasonographic images during an ultrasonographic fetal evaluation, comprising:performing an analysis of a plurality of ultrasonographic images captured by an ultrasonographic probe during an evaluation of a fetus;
automatically identifying a plurality of locations of a plurality of anatomical landmarks of at least one reference organ or tissue or body fluid of said fetus in said plurality of ultrasonographic images based on an outcome of said analysis;
automatically and indirectly localizing a region of interest (ROI), different than said plurality of anatomical landmarks, in at least some of said plurality of ultrasonographic images by:
calculating for each of said plurality of anatomical landmarks, a plurality of consecutive contour lines encircling said each of said plurality of anatomical landmarks in a predefined plurality of different distances from a contour of said each of said plurality of anatomical landmarks,
selecting for each of said plurality of anatomical landmarks, at least one contour line which is at least one of said plurality of consecutive contour lines according to a pre-determined distance,
defining a region bound by intersections of said selected contour lines of said plurality of anatomical landmarks and
determining said defined bound region as containing said region of interest (ROI); and
concealing said bound region in a presentation of said at least some ultrasonographic images during said evaluation;
wherein said plurality of anatomical landmarks are imaged in said presentation and not concealed by said ROI.

US Pat. No. 9,986,907

SYSTEM AND METHOD FOR OBJECTIVE CHROMATIC PERIMETRY ANALYSIS USING PUPILLOMETER

Tel HaShomer Medical Rese...

1. A pupillometer comprising:a processor;
at least one camera; and
a testing compartment provided in the form of a substantially hemispheric bowl; wherein
the substantially hemispheric bowl comprises a plurality of chromatic beam emitters arranged about a visual field forming a plurality of visual field testing points,
the chromatic beam emitters generate a plurality of chromatic stimuli about the visual field testing points,
the chromatic stimuli comprise a first chromatic beam stimulus and a second chromatic beam stimulus,
at least one of the first chromatic beam stimulus and the second chromatic beam stimulus employs a wavelength that stimulates ganglion cells,
the testing compartment further comprises a light adaptation emitter,
the inner surface further comprises a fixation point opposite a subject's line of sight,
the at least one camera records pupil contraction in response to the first and second chromatic beam stimuli,
the processor controls the chromatic beam emitters and the stimulus parameters of the chromatic beam emitters, and
the processor processes data associated with and generated by the first and second chromatic beam stimuli and the camera and is programmed to
generate quantitative pupillary light reflex (PLR) measurements of a PLR in response to chromatic beam stimuli presented at the plurality of visual field testing points,
determine ratios of the quantitative PLR measurements at the plurality of visual field testing points, wherein each of the ratios at each testing point represents a quantitative PLR measurement at the first chromatic beam stimulus relative to a quantitative PLR measurement at the second chromatic beam stimulus, and
determine the state of health of the eye utilizing the ratios, wherein (i) the first chromatic beam stimulus employs a shorter-wavelength chromatic beam, relative to the second chromatic beam stimulus, (ii) the second chromatic beam stimulus employs a longer-wavelength chromatic beam, relative to the first chromatic beam stimulus, and (iii) the wavelengths of the first chromatic beam stimulus and the second chromatic beam stimulus are selected from the visual spectrum spanning from about 390 nm to about 750 nm.
US Pat. No. 9,987,326

KLOTHO PROTEIN AND RELATED COMPOUNDS FOR THE TREATMENT AND DIAGNOSIS OF CANCER

Tel HaShomer Medical Rese...

1. A method comprising:administering to a subject with cancer a pharmaceutically effective amount of a composition comprising:
(a) a soluble polypeptide consisting of an extracellular domain of a klotho protein, wherein the klotho protein is encoded by one of SEQ ID NOS: 1, 2, 3, 4, 5, 11, 12, 13, 14 or 15; or
(b) a soluble polypeptide consisting of an amino acid sequence selected from the group consisting of residues 31 to 982 of SEQ ID NO: 1, residues 34 to 1012 of SEQ ID NO: 1, residues 34 to 549 of SEQ ID NO: 2, residues 31 to 982 of SEQ ID NO: 3, and residues 36 to 1014 of SEQ ID NO: 3; or
(c) a soluble polypeptide consisting of an amino acid sequence having at least 80% homology to a polypeptide defined in (a) or (b); and
a pharmaceutically-acceptable carrier.
US Pat. No. 9,771,567

KLOTHO VARIANT POLYPEPTIDES

TEL HASHOMER MEDICAL RESE...

1. An isolated polypeptide comprising an amino-acid residue sequence selected from the group consisting of:
SEQ ID NO: 1 or a sequence at least 95% identical thereto;
residues 29-1012 of SEQ ID NO:1 or a sequence at least 95% identical thereto;
residues 1-980 of SEQ ID NO:1 or a sequence at least 95% identical thereto;
residues 29-980 of SEQ ID NO:1 or a sequence at least 95% identical thereto;
residues 1-568 of SEQ ID NO:1 or a sequence at least 95% identical thereto;
residues 29-568 of SEQ ID NO:1 or a sequence at least 95% identical thereto;
residues 34-549 of SEQ ID NO:1 or a sequence at least 95% identical thereto;
SEQ ID NO:8 or a sequence at least 95% identical thereto;
residues 29-549 of SEQ ID NO:8 or a sequence at least 95% identical thereto; and
residues 34-549 of SEQ ID NO:8 or a sequence at least 95% identical thereto,
wherein:
the L-Glu of residue 414 is substituted with L-?-Gln.

US Pat. No. 9,688,697

RNA POLYMERASE I INHIBITORS AND USES THEREOF

Tel HaShomer Medical Rese...

1. A compound represented by Formula Ia or Ic:

wherein E forms a chemical moiety other then carbonyl, capable of interfering with a hydrogen binding capacity of the compound.
US Pat. No. 10,028,999

PAR-1 BASED THERAPEUTIC CONJUGATES AND USES THEREOF

TEL HASHOMER MEDICAL RESE...

1. A peptide conjugate comprising:an alpha-amino protecting moiety,
a peptide consisting of the amino acid sequence selected from the group of Asp-Pro-Arg and SEQ ID NOs: 1-17, and
a protease-disabling moiety,
wherein the peptide is bound to the alpha-amino protecting moiety and to the protease-disabling moiety, wherein the protease-disabling moiety is chloromethylketone or derivatives thereof and wherein the alpha-amino protecting moiety is tosyl or derivatives thereof.
US Pat. No. 9,975,944

SYNTHETIC PEPTIDES FOR THE TREATMENT OF AUTOIMMUNE DISEASES

TEL HASHOMER MEDICAL RESE...

1. A synthetic peptide comprising the amino acid sequence set forth in SEQ ID NO: 1.
US Pat. No. 9,737,571

COMPOSITIONS OF AQUATIC ORIGIN FOR PREVENTION OF CELL ADHESION AND METHODS OF USING SAME

TEL HASHOMER MEDICAL RESE...

1. A method of inhibiting or reducing adhesion of bacteria to a surface comprising administering an effective amount of an
isolated and purified protein obtained from Actinia equina, wherein the protein has a molecular weight of around 60 KDa and
the sequence of SEQ ID:1, to said surface.
US Pat. No. 9,770,469

METHODS OF REPROGRAMMING RENAL CELLS

Tel HaShomer Medical Rese...

1. A method of reprogramming a differentiated adult epithelial renal cell to a cell having a progenitor phenotype, the method
comprising transfecting the differentiated renal cell with a nucleic acid construct comprising a nucleic acid sequence encoding
Oct4, thereby reprogramming the differentiated adult epithelial renal cell to a cell having a progenitor phenotype, and wherein
said progenitor phenotype comprises Six2 and/or Osr1 expression and cell clonogenicity.

US Pat. No. 9,782,387

COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES

Tel HaShomer Medical Rese...

1. A method of treating multiple myeloma or myelofibrosis in a subject in need thereof, the method comprising administering
to the subject a therapeutically effective amount of a pentyl 6-(furan-2-yl)-3-methyl-4-oxo-1, 5, 6, 7-tetrahydroindole-2-carboxylate:

thereby treating the multiple myeloma or the myelofibrosis.
US Pat. No. 10,113,170

PREVENTING AND TREATING INFLAMMATORY SKIN DISEASES

TEL HASHOMER MEDICAL RESE...

1. A method of treating an inflammatory skin disease, condition or lesion in a human subject, comprising the step of administering to the subject a therapeutically effective amount of a composition comprising, as the only active ingredient, at least one sequence selected from mature miR-197 [SEQ ID NO: 8], mature miR-99a [SEQ ID NO: 17], or a combination thereof, and, optionally, at least one additional sequence selected from the group consisting of pre-miR-197 [SEQ ID NO: 9], pre-miR-99a [SEQ ID NO: 16], pre-miR-Let7c [SEQ ID NO: 12], mature miR-Let7c [SEQ ID NO: 13], pre-miR-125b-2 [SEQ ID NO: 14], mature miR-125b-2 [SEQ ID NO: 15], or any combination thereof.

US Pat. No. 10,022,382

RNA POLYMERASE I INHIBITORS AND USES THEREOF

Tel HaShomer Medical Rese...

1. A method of treating relapsing-remitting multiple sclerosis in a subject, the method comprising administering to the subject a therapeutically effective amount of the compound represented by Formula lb:
wherein G is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, alkoxy, thioalkoxy, thiol, hydroxyl, aryloxy, and thioaryloxy.
US Pat. No. 9,758,831

METHODS OF PREDICTING CLINICAL COURSE AND TREATING MULTIPLE SCLEROSIS

Tel HaShomer Medical Rese...

1. A composition comprising a probeset for classifying a disease course in a subject diagnosed with multiple sclerosis comprising
a plurality of oligonucleotides and no more than 50 oligonucleotides, wherein said plurality of oligonucleotides comprise
oligonucleotides that specifically recognize RRN3, POLR1D and LRPPRC; and a biological sample of a subject diagnosed with
multiple sclerosis.
US Pat. No. 10,058,710

DEVICE AND METHOD FOR REDUCING THE PERMEABILITY OF THE CORNEA

Tel Hashomer Medical Rese...

1. A method of treating an eye of a subject, comprising i) applying a changing magnetic field; ii) measuring penetration of fluorescein from the corneal surface to anterior chamber of said eye; and iii) selecting a magnetic field strength sufficient to reduce corneal permeability.
US Pat. No. 10,179,151

METHODS OF TRANSDIFFERENTIATION AND METHODS OF USE THEREOF

ORGENESIS LTD., Tel Aviv...

1. A method of manufacturing a population of human insulin producing cells, the method comprising the steps of:(a) obtaining adult human liver tissue;
(b) processing said liver tissue to recover primary adult human liver cells;
(c) propagating and expanding said primary adult human liver cells to a predetermined number of cells;
(d) transdifferentiating said expanded cells, wherein said transdifferentiating comprises:
(1) infecting said expanded cells with at least one expression vector, said infecting occurring at a first time period,
(i) wherein said at least one expression vector comprises an adenoviral vector comprising a nucleic acid encoding a PDX-1 polypeptide and an expression vector comprising an adenoviral vector comprising a nucleic acid encoding a second pancreatic transcription factor polypeptide selected from NeuroD1 and Pax4, wherein said infecting with said adenoviral vectors occurs at the same time,
or
(ii) wherein said at least one expression vector comprises an adenoviral vector comprising a nucleic acid encoding a PDX-1 polypeptide and a second pancreatic transcription factor polypeptide selected from NeuroD1 and Pax4;
and
(2) infecting said expanded infected cells of (1) with an adenoviral vector comprising a nucleic acid encoding a MafA polypeptide, said infecting occurring at a second time period, wherein said second time period is after said first time period;
and
(e) harvesting said transdifferentiated expanded cells;
thereby manufacturing said population of human insulin producing cells having an increased insulin content, or increased glucose regulated insulin secretion, or increased glucose regulated C-peptide secretion, or any combination thereof, compared with control non-transdifferentiated liver cells.

US Pat. No. 10,173,056

METHODS FOR IMPROVING MALE FERTILITY

Tel Hashomer Medical Rese...

1. A method for improving male fertility comprisinggenerating a positive electric current within the range of 10 ?A to 500 ?A from a power source; and
contacting at least one site of the scrotum of a male subject with at least one positive electrode connected to said current; and
applying, prior to intercourse, the positive electric current to the at least one site thereby improving male fertility towards induction of pregnancy via natural intercourse.

US Pat. No. 10,363,169

SYSTEM AND METHOD FOR TREATING AN EYE

TEL HASHOMER MEDICAL RESE...

1. A method, comprising:providing a system that comprises a laser source and a hardware-implemented beam-shaping device comprising one or more optical elements;
generating electromagnetic radiation by the laser source; and
irradiating one or more regions of a trabecular meshwork of an eye with the electromagnetic radiation generated by the laser source, by directing the electromagnetic radiation using the beam-shaping device through an entire thickness of a scleral limbus of the eye without any contact with the eye.

US Pat. No. 10,285,852

SUBRETINAL DELIVERY OF THERAPEUTIC COMPOSITIONS

TEL HASHOMER MEDICAL RESE...

1. A device suitable for delivering a therapeutic composition to an eye of a subject, comprising:a guide comprising an eye-contacting surface configured to make contact with a surface of said eye for fixing a relative position of said guide to the eye, said guide having a proximal end, a distal end and a guide channel opened at said guide distal end;
a piercer configured to be inserted through said guide channel and to emerge axially with a distal end of said piercer extending to make an incision in a sclera of said eye without piercing the sensory retina, when said eye-contacting surface is in contact with an anterior portion of said eye near a target location for making said incision; and
an injector configured to be inserted through said guide channel and to emerge axially with a distal tip of said injector, for injecting said therapeutic composition via said distal tip of said injector into said incision made by said piercer;
wherein said guide comprises a retainer for retaining said piercer when making said incision and for retaining said injector when injecting said therapeutic composition, and wherein said retainer prevents said distal tip of said injector from extending into said incision further than said retainer permits said piercer to extend when said piercer is inserted into said guide for making said incision.

US Pat. No. 10,275,680

MAGNETIC RESONANCE MAPS FOR ANALYZING TISSUE

Tel HaShomer Medical Rese...

1. Apparatus for analyzing magnetic resonance images, comprising:an input circuit configured for receiving a first and a second Magnetic Resonance Imaging (MRI) scan of a tissue at a beginning and end of a predetermined time interval post contrast agent administration, wherein said tissue is a brain of a subject and wherein said predetermined time interval is at least fifty minutes;
a memory for storing said first and said second MRI scans;
an image processor having a circuit configured for subtracting said first and said second MRI scans from one another to distinguish between two primary populations, a slow population, in which contrast clearance from the tissue is slower than contrast accumulation, and a fast population in which contrast clearance is faster than contrast accumulation; and
an output circuit configured for converting said scans to a displayed subtraction map on which distributions of said two primary populations are distinguished,
wherein said fast population is displayed as a tumor that is selected from a group consisting of a tumor demonstrating hyper cellularity, a tumor demonstrating mitoses, a tumor demonstrating high Ki67, a tumor demonstrating pseudo-palisading necrosis, and any combination thereof, and
wherein said slow population is displayed as a non-tumoral tissue region selected from a group consisting of (i) treatment effect, (ii) pseudo-progression, (iii) radiation-necrosis, (iv) inflammation, (v) post-surgical changes, (vi) tumor necrosis, and any combination thereof.

US Pat. No. 10,292,689

BODY PART REPOSITIONING APPARATUS AND METHOD

Tel HaShomer Medical Rese...

1. A completely atraumatic method for repositioning a left atrial appendage (LAA) of a heart, comprising:transseptally and transvasculary introducing a guide instrument within a human body; wherein said guide instrument comprising a suction channel passing through a lumen of said guide instrument terminating with a concave holder, said suction channel and said concave holder are enclosed within said lumen of said guide instrument during said introducing;
distally positioning said guide instrument in a left atrium (LA) distal to an ostium of said LAA;
extending said suction channel and radially expanding said concave holder from said lumen of said guiding instrument into said LAA;
holding a portion of the LAA by said concave holder by applying suction through said suction channel without imparting damage to the LAA, until said portion of the LAA is held and drawn into a lumen of said concave holder;
fully inverting said held LAA portion into said LA while said held LAA portion is outside said lumen of said guide instrument;
extending forward and expanding a fastener from said lumen of said guide instrument, wherein said fastener is shaped and sized to be enclosed within said lumen of said guide instrument during said introducing; and
fastening said fully inverted LAA portion by said fastener;
wherein all of said steps being performed without imparting damage to the LAA,
and
wherein said fastening comprising actuating said fastener from within said lumen of said guide instrument in such a way to be wrapped around said fully inverted LAA portion to permanently prevent return thereof to its normal position and to close said LAA.

US Pat. No. 10,292,816

PROSTHETIC MITRAL VALVE

TEL HASHOMER MEDICAL RESE...

1. A method for use with a prosthetic valve that is configured to be deployed within a native atrio-ventricular valve of a heart of a mammalian subject, the native atrio-ventricular valve including a valve annulus, valve leaflets, chords, and papillary muscles, the method comprising:placing a valve frame within the subject's heart, the valve frame including:
a valve frame body that is configured to support the prosthetic valve within the native atrio-ventricular valve, and that includes an atrial portion and a ventricular portion, and
at least one arm that is configured to extend from the ventricular portion of the valve frame;
subsequently, deploying the at least one arm among the chords of the native atrio-ventricular valve;
subsequently, rotating at least a portion of the valve frame, in a direction in which an interior of the arm faces, such as to cause the arm to (a) pull the native atrio-ventricular valve radially inward toward the valve frame, and (b) twist the native atrio-ventricular valve around the valve frame, by recruiting and deflecting at least a portion of the chords; and
subsequently, causing the frame body of the valve frame to radially expand, such as to trap the native valve leaflets in a partially closed and twisted configuration, to thereby at least partially seal a space between the native atrio-ventricular valve and the prosthetic valve.
US Pat. No. 10,266,579

SYNTHETIC SOMATOSTATIN RECEPTOR LIGANDS

TEL HASHOMER MEDICAL RESE...


wherein:
chemical entity A is a chemical entity Xxx9-A? wherein Xxx9 is an amino acid residue directly bonded to the Phe residue located at the C-terminus of said selected sequence and that includes a sulfur atom;
A? is any chemical entity; and
said selected amino acid residue sequence is cyclized with a sulfur-sulfur bond between said sulfur atom of Xxx9 and a sulfur atom of Cys, HCys or DCys of said selected amino acid residue sequence.
US Pat. No. 10,465,004

FRIZZLED RECEPTOR ANTIBODIES FOR TREATMENT OF CANCER

Tel HaShomer Medical Rese...

1. A method for treating a tumor characterized by elevated expression of a Frizzled7 receptor in a subject, said method comprising the step of administering a therapeutically effective dose of an isolated antibody or antigen-binding portion thereof that binds to a Frizzled7 receptor, wherein the antibody binds to the cytoplasmic portion of said receptor and wherein the antibody has complementarity determining regions (CDRs) of the antibody produced by the hybridoma cell line 288-1 deposited in the American Type Culture Collection, Manassas, Va., USA, under the Registration Number PTA-123746; or the antibody produced by the hybridoma cell line 288-5 deposited in the American Type Culture Collection, Manassas, Va., USA, under the Registration Number PTA-123744.

US Pat. No. 10,456,295

MEDICAL DEVICE, ASSEMBLY AND METHOD FOR CREATING A CHANNEL IN SOFT TISSUE

TEL HASHOMER MEDICAL RESE...

1. A device for creating a channel having predetermined dimensions in an eye wall, the device comprising an elongated member extending along a longitudinal axis X between a first end and a second end;said first end comprising an engagement element configured for engagement with a grip unit comprising a rotor to cause rotation of said elongated member about said longitudinal axis X upon actuation of the rotor to create said channel;
said second end comprising a tissue piercing tip configured for piercing the eye wall during insertion of the device along said longitudinal axis X into the eye wall;
said elongated member comprising a segment proximal to the second end extending along said longitudinal axis X and configured for creating said channel by said rotation, said segment having an external surface having a circumference C and comprising:
at least one depression axially extending along at least a portion of said segment; and
one or more blades with a cutting edge, extending peripherally beyond said circumference C of said external surface, by a distance defining a cutting thickness, the one or more blades extending along at least part of said segment;
said device comprising a protective member configured and operable to:
be fixedly attached to the grip unit at a proximal end of the protective member,
have a lumen surrounding the elongated member and in which the elongated member is entered from its first end to be engaged by the engagement element with the grip unit,
have a predetermined length defining a length of the elongated member that penetrates the eye,
have a shape configured to penetrate through conjunctiva tissue of the eye wall and to form a stopper to prevent excessive penetration of the elongated member into sclera tissue of the eye wall and to block the device from penetrating the eye to an extent that causes damage to inside of the eye, and
be static during rotation of the elongated member thereby protecting the surrounding conjunctiva tissue during the channel creation in the eye wall.

US Pat. No. 10,264,962

SYSTEM AND METHOD FOR OBJECTIVE CHROMATIC PERIMETRY ANALYSIS USING PUPILLOMETER

Tel Hashomer Medical Rese...

1. A pupillometer system comprising:a computer having a processor;
at least one camera, wherein the at least one camera is in communication with the computer; and
a testing compartment provided in the form of a substantially hemispheric bowl, wherein:
the substantially hemispheric bowl comprises a plurality of chromatic beam emitters arranged about a visual field forming a plurality of visual field testing points,
the plurality of chromatic beam emitters generate a plurality of stimuli about the plurality of visual field testing points,
a first chromatic stimulus of the plurality of stimuli stimulates a first anatomical structure comprising at least one of the following: one or more ganglions, one or more rods, and one or more cones,
a second chromatic stimulus of the plurality of stimuli stimulates a second anatomical structure comprising at least one of the following: one or more ganglions, one or more rods, and one or more cones, wherein the first anatomical structure is different than the second anatomical structure,
the at least one camera records a pupil response of one or more eyes in response to the first chromatic stimulus and the second chromatic stimulus,
the processor controls the plurality of chromatic beam emitters and one or more stimulus parameters of the plurality of chromatic beam emitters,
the processor processes data associated with and generated by the first chromatic stimulus and the second chromatic stimulus and the at least one camera, and
the processor is programmed to:
generate quantitative pupillary light reflex (PLR) measurements of the PLR in response to the plurality of stimuli presented at the plurality of visual field testing points,
determine at least one PLR response ratio, wherein the at least one PLR response ratio is a relationship between a response measurement based on the first chromatic stimulus generated by at least one visual field testing point of the plurality of visual field testing points and a response measurement based on the second chromatic stimulus generated by at least one visual field testing point of the plurality of visual field testing points, and
determine a state of health of the one or more eyes utilizing the at least one PLR response ratio.

US Pat. No. 10,258,230

PUPILLOMETERS AND SYSTEMS AND METHODS FOR USING A PUPILLOMETER

Tel Hashomer Medical Rese...

1. A pupillometer comprising:a testing compartment;
at least one ocular;
at least one camera; and
a computing device, wherein
the testing compartment comprises a plurality of chromatic beam emitters arranged about a visual field of the pupillometer,
selected ones of the plurality of chromatic beam emitters are structurally configured to generate chromatic stimuli within a blue portion of a visible electromagnetic spectrum,
selected ones of the plurality of chromatic beam emitters are structurally configured to generate chromatic stimuli within a red portion of the visible electromagnetic spectrum,
the at least one ocular is positioned to facilitate exposure of light sensitive ocular structures of an eye to blue and red chromatic stimuli of the plurality of chromatic beam emitters,
the at least one camera is configured to capture temporal images of a pupil of a subject, the temporal images indicating temporal pupil contraction of the eye in response to the blue and red chromatic stimuli of the plurality of chromatic beam emitters, and
the computing device is programed to
control emission wavelength, intensity, and duration of the plurality of chromatic beam emitters,
receive images from the at least one camera,
process the temporal images of the pupil captured by the at least one camera to generate a signal representative of the eye in response to the blue and red chromatic stimuli of the plurality of chromatic beam emitters, and
drive the plurality of chromatic beam emitters to generate chromatic stimuli within the blue and red portions of the visible electromagnetic spectrum such that red chromatic intensity is at least 2 times greater than blue chromatic stimuli intensity for generation of the signal.